Skip to content
Screener

CalAmp CAMP Net Income

Net Income at other companies

Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$50M-144%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$56.62M-112%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$160.72M+514%
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
-$2.54M+49.6%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
-$46.64M-73.5%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
-$20.67M-13,319%

Segments

By segment

See full
R&D-$33.53M-166%

Other financials

Income statement

See full
Revenue$1.8M+18.8%
Operating income-$13.4M-2.7%
EPS (diluted)-$0.58+6.5%

Balance sheet

See full
Cash & equivalents$88.0M+116%
Total debt$2.4M-66.8%
Total equity-$693.0K-102%
Total assets$93.4M+82.2%

Cash flow

See full
Operating cash flow-$12.7M-22.7%
CapEx$129.0K
Free cash flow-$12.8M-23.9%

Valuation

See full
Market cap$263.56M+766%
Enterprise value$177.91M-5,871%
P/S62.5×+52.4×

Profitability

See full
Operating margin-1,254.2%-287pp
Net margin-2,543.7%+2,321pp
FCF margin-1,254%

Returns & leverage

See full
Return on equity-209.3%
Debt / equity0.1×-0.1×
Current ratio4.7×-0.9×

Where this comes from

Reported directly by CalAmp in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: CalAmp’s 10-Q, filed August 13, 2026.

Filed
Aug 13, 2026, 4:23 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-056760
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Change in fair value of derivative tranche liability(20,930)(27,118)
Other (expense) income(27)(12)(9)67
Total other (expense) income, net(20,150)441(25,410)1,108
Net loss$(33,530)$(12,587)$(51,861)$(25,020)
Net loss per share attributable to common stockholders, basic and diluted$(0.58)$(0.62)$(0.90)$(1.24)
Weighted-average shares of common stock outstanding, basic and diluted57,929,66220,159,66657,926,68520,155,161
Net loss attributable to common stockholders$(33,530)$(12,587)$(51,861)$(25,020)
Other comprehensive income (loss)

Item 1. Financial Statements (Unaudited)

FAQ

What is CalAmp's net income?
CalAmp (CAMP) reported net income of -$33.53M in Q2 2026.
How has CalAmp's net income changed year-over-year?
CalAmp's net income decreased by 166.4% year-over-year, from -$12.59M to -$33.53M.
What is the long-term trend for CalAmp's net income?
Over 2 years (2023 to 2025), CalAmp's net income has grown at a 27.7% compound annual growth rate (CAGR), from -$49.29M to -$80.4M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.

Ask your AI about CalAmp's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude